Impact of Omicron variant on the response to SARS-CoV-2 mRNA Vaccination in multiple myeloma

Storti, Paola; Marchica, Valentina; Vescovini, Rosanna; Franceschi, Valentina; Russo, Luca; Raimondi, Vincenzo; Toscani, Denise; Burroughs‐Garcia, Jessica; Costa, Federica; Palma, Benedetta Dalla; Soressi, Naomi; Giaimo, Mariateresa; Iannozzi, Nicolas Thomas; Notarfranchi, Laura; Sammarelli, Gabriella; Donofrío, Gaetano; Giuliani, Nicola

doi:10.1101/2022.02.25.22271501

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [68] A study in patients with monoclonal gammopathies at different stages of disease, including multiple myeloma (n = 40), showed that neutralizing antibody responses against Omicron (B.1.1.529) were reduced compared to the wild-type strain following the primary vaccine regimen, but were improved following a booster dose. [69] …”

Section: Immunocompromised Patientsmentioning

confidence: 99%

Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest

Moss

Bérenbaum

Curigliano

et al. 2022

Vaccine

View full text Add to dashboard Cite

Section: Immunocompromised Patientsmentioning

confidence: 99%

Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest

Moss

Bérenbaum

Curigliano

et al. 2022

Vaccine

View full text Add to dashboard Cite

Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis

Harandi,

Fallahtafti,

Karimi

et al. 2024

BMC Geriatr

View full text Add to dashboard Cite

Background Impaired immune response in multiple myeloma renders the patients vulnerable to infections, such as COVID-19, and may cause worse response to vaccines. Researchers should analyze this issue to enable the planning for special preventive measures, such as increased booster doses. Therefore, this meta-analysis aimed to evaluate the response and efficacy of COVID-19 vaccines in patients with multiple myeloma. Methods This meta-analysis followed PRISMA 2020 guidelines, conducting a comprehensive database search using specified keywords. Study selection involved a two-phase title/abstract and full-text screening process. Data extraction was performed by two researchers, and statistical analysis involved meta-analysis, subgroup analysis based on vaccine dosage and study time, random effects meta-regression, and heterogeneity testing using the Q test. Results The meta-analysis revealed that patients with multiple myeloma (MM) had a lower likelihood of developing detectable antibodies after COVID-19 vaccination compared to healthy controls (Log odds ratio with 95% CI: -3.34 [-4.08, -2.60]). The analysis of antibody response after different doses showed consistent lower seropositivity in MM patients (after first dose: -2.09, [-3.49, -0.69], second: -3.80, 95%CI [-4.71, -3.01], a booster dose: -3.03, [-5.91, -0.15]). However, there was no significant difference in the mean level of anti-S antibodies between MM patients and controls (Cohen’s d -0.72, [-1.86, 0.43]). Evaluation of T-cell responses indicated diminished T-cell-mediated immunity in MM patients compared to controls. Seven studies reported clinical response, with breakthrough infections observed in vaccinated MM patients. Conclusions These findings highlight the impaired humoral and cellular immune responses in MM patients after COVID-19 vaccination, suggesting the need for further investigation and potential interventions.

show abstract

Impact of Omicron variant on the response to SARS-CoV-2 mRNA Vaccination in multiple myeloma

Cited by 2 publications

References 45 publications

Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest

Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest

Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis

Contact Info

Product

Resources

About